INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Acelyrin, Inc. and Encourages Investors with Losses to Contact the Firm
News provided byACCESSWIRE
Sep 19, 2023, 8:45 AM ET
LOS ANGELES, CA / ACCESSWIRE / September 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Acelyrin, Inc. ("Acelyrin" or "the Company") (NASDAQ:SLRN) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Acelyrin is the subject of a report published by Dow Jones Newswires on September 11, 2023. According to the report, "The Los Angeles-based pharmaceutical company said part B of its Phase 2b/3 trial examining the use of izokibep for the treatment of moderate-to-severe Hidradenitis Suppurativa (HS), an inflammatory skin condition, didn't meet statistical significance for its primary endpoint by week 16." Based on this news, shares of Acelyrin fell by more than 60% on the next day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at email@example.com.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
SOURCE: The Schall Law Firm
View source version on accesswire.com:
NOTE: This content is not written by or endorsed by "KOLR/KOZL/KRBK", its advertisers, or Nexstar Media Inc.